Cannabis Use in Your 20s and 30s Linked to Earlier Psychosis: Why Age Alone May Not Make It Safer

Using cannabis in adulthood may still be associated with an earlier onset of psychosis, according to new research that challenges a common assumption about the so-called “safe age” for cannabis use. The findings are particularly relevant to people in their 20s and 30s who may believe that delaying cannabis until the brain has largely matured removes much of its potential psychiatric risk.

The emerging evidence suggests the issue is more complicated. A major 2026 analysis led by researchers from Australia examined 149 studies involving more than 71,000 people and found that adults who used cannabis developed psychosis earlier than non-users, with the difference varying substantially across age groups. The researchers reported earlier onset by approximately 1.6 to 6.3 years depending on the age category examined.

At the same time, the research does not establish that cannabis inevitably causes psychosis in every adult who uses it. Psychosis has multiple risk factors, including genetics, other substance use and underlying mental-health vulnerability. The relationship between cannabis exposure and psychosis is therefore one of risk, not certainty.

The more important takeaway is that turning 25 is not a biological switch that makes cannabis harmless.

What is psychosis?

Psychosis describes a group of symptoms in which a person has difficulty distinguishing what is real from what is not. It can involve hallucinations, delusions, disorganised thinking or significant changes in behaviour and perception.

Psychosis can occur in several psychiatric and medical conditions, including schizophrenia-spectrum disorders, bipolar disorder and severe mood disorders. It can also occur temporarily in association with certain drugs or medical conditions.

A first episode of psychosis is clinically important because earlier recognition and treatment can improve the chances of recovery and reduce disruption to education, employment, relationships and everyday functioning.

That is why researchers are interested not only in whether cannabis increases the probability of psychosis, but also in whether cannabis changes when psychosis first appears.

What does the new research add?

The 2026 research is notable because it challenges a research narrative that has often concentrated heavily on adolescence.

Adolescent cannabis exposure has long been studied because the brain continues developing through adolescence and young adulthood. Previous research has found associations between cannabis use, particularly frequent or high-potency use, and psychotic symptoms or earlier psychosis.

But the new analysis asks a different question: What happens when cannabis exposure begins later?

Its findings suggest that the association with earlier psychosis does not simply disappear when people move beyond adolescence.

That matters because public conversations sometimes reduce the issue to brain development and age 25. The reality is more nuanced. Brain maturation occurs gradually and differently across regions and individuals, and the absence of adolescent exposure does not mean later cannabis use carries no psychiatric risk.

Does cannabis in your 20s or 30s cause psychosis?

No study can reasonably conclude that every episode of psychosis among cannabis users was caused by cannabis.

The distinction between association and causation is essential here.

People who use cannabis may differ from non-users in several other ways. They may have different patterns of tobacco or alcohol use, socioeconomic circumstances, family histories, mental-health vulnerabilities or exposure to other drugs.

There is also a phenomenon known as reverse causation or self-medication. Some people who are developing psychiatric symptoms may begin using cannabis because of changes in mood, anxiety, sleep or perception before they receive a formal diagnosis.

However, the evidence becomes more concerning when several studies show a consistent temporal relationship in which cannabis use precedes psychotic symptoms and heavier or more frequent use is associated with greater risk.

Previous research has found that earlier cannabis exposure can be associated with younger ages of psychosis onset, while studies of first-episode psychosis have reported that cannabis use commonly begins before the emergence of full psychotic symptoms.

Why the “wait until 25” idea can be misleading

The popular idea that people can simply wait until age 25 before using cannabis comes from a broader discussion about brain development. But it turns a complicated biological process into an arbitrary birthday.

There is no single day on which the brain suddenly changes from developing to fully mature.

Different brain networks mature at different rates, and factors such as genetics, environment, sleep, stress and substance exposure can influence brain function throughout adulthood.

More importantly, the new evidence suggests that the relationship between cannabis and psychosis cannot be explained solely by whether someone has passed a particular age threshold.

Age may influence vulnerability, but it does not define a zero-risk point.

High-potency cannabis may be an especially important concern

Another issue frequently missing from casual discussions about cannabis is potency.

Cannabis products can contain very different concentrations of tetrahydrocannabinol, or THC, the principal psychoactive compound responsible for the drug’s intoxicating effects.

Research has repeatedly identified stronger associations between high-potency cannabis and psychosis than between lower-potency products and psychotic outcomes.

A previous study of first-episode psychosis patients found that people who used high-potency cannabis daily had particularly early psychosis onset. Other longitudinal research has also associated high-potency cannabis exposure with an increased likelihood of later psychotic experiences.

This means that “I only use cannabis” does not provide enough information to understand risk. Frequency, potency, pattern of use and individual vulnerability all matter.

Frequency may matter as much as age

Another important insight from the research is that cannabis exposure should not be treated as a simple yes-or-no variable.

Someone who uses cannabis once is not in the same exposure category as someone who uses a high-THC product every day.

Earlier research has reported dose-response patterns in which more frequent cannabis use is associated with greater psychosis risk. Daily use, particularly of high-potency cannabis, has emerged as a recurring concern across studies.

This does not mean occasional use has no risk. Rather, it suggests that public-health messages should move beyond simplistic statements such as “cannabis is safe” or “cannabis always causes schizophrenia.”

The actual risk exists along a spectrum.

What happens in the brain?

Scientists are still investigating the biological mechanisms that could explain the relationship between cannabis and psychosis.

THC interacts with the body’s endocannabinoid system, which plays roles in processes including mood, memory, reward, stress responses and cognition.

One proposed explanation is that THC can influence brain signalling involved in perception and information processing. In people who are already biologically vulnerable to psychosis, these effects could potentially contribute to the emergence or acceleration of symptoms.

Researchers have also investigated whether repeated exposure may alter neural systems over time. However, the exact mechanisms linking cannabis exposure with the timing of psychosis remain an active area of research.

It would therefore be premature to describe the latest findings as proof of a specific “neurotoxic mechanism.”

Genetics may determine who is most vulnerable

Not everyone who uses cannabis develops psychosis. This is one of the most important facts to keep in mind.

Researchers believe vulnerability is influenced by a combination of genetic, developmental and environmental factors.

A person with a strong family history of psychotic disorders may have a different baseline risk from someone without that history. Cannabis exposure may interact with that underlying vulnerability rather than acting as an independent cause in every individual.

This helps explain why two people can use similar amounts of cannabis but have very different outcomes.

The absence of symptoms in one cannabis user therefore cannot be used as evidence that the drug is harmless for another person.

Could cannabis be triggering psychosis that was already developing?

This is one of the hardest questions in the field.

Psychotic disorders often develop gradually. Subtle changes in thinking, social functioning, sleep, motivation or perception can occur before a full psychotic episode becomes obvious.

Some people may begin using cannabis during this period because they are experiencing distress or unusual sensations.

That creates a difficult research problem: did cannabis contribute to the onset of psychosis, or did emerging psychosis increase cannabis use?

Evidence from longitudinal studies helps address this problem because researchers can examine cannabis exposure before symptoms become apparent. A community-based first-episode psychosis study found that cannabis exposure preceded the onset of psychotic symptoms in most participants who had used cannabis, while earlier first exposure was associated with younger ages of prodrome and psychosis onset.

These findings do not eliminate all uncertainty, but they make the relationship more difficult to explain solely through self-medication.

What about medicinal cannabis?

The discussion becomes more complicated when cannabis is used for medical purposes.

Medicinal cannabis products can contain different cannabinoids and varying concentrations of THC. A prescription or medical recommendation does not automatically mean that a product carries no psychiatric risk.

The latest Australian research has raised particular questions about the rapid expansion of medicinal-cannabis prescribing and the need for better evidence regarding the mental-health effects of THC-containing products.

That does not mean all medicinal cannabis is dangerous or that legitimate medical uses should be dismissed. It means clinicians need to consider the composition of the product, the reason it is being prescribed, the patient’s psychiatric history and potential risks.

Cannabis and psychosis: what the evidence currently suggests

The warning signs people should not ignore

The practical value of this research is not simply telling people whether to use cannabis. It is also helping people recognise when professional assessment may be necessary.

Early warning signs of psychosis can include unusual suspiciousness, hearing or seeing things that others do not, strongly held beliefs that seem disconnected from reality, severe confusion, marked social withdrawal or significant changes in behaviour and functioning.

Sleep disruption, anxiety and unusual perceptions can have many causes and do not automatically indicate psychosis. But new or worsening symptoms deserve attention, particularly when they appear after cannabis use or are accompanied by escalating substance use.

Someone experiencing hallucinations, severe paranoia, confusion or a loss of contact with reality should seek urgent medical or mental-health assessment rather than attempting to manage the situation through cannabis or other substances.

A better public-health message: there is no magic safe birthday

The biggest insight from the latest research may be that public-health messaging needs to become more sophisticated.

Telling teenagers that cannabis can affect Mental Health is important. But telling young adults that the danger essentially disappears after 25 would create a misleading impression.

A more accurate message would be:

Risk is influenced by age, but age alone does not determine cannabis-related psychosis risk.

People who use cannabis should also understand that higher-THC products and frequent use appear to be particularly concerning. Those with a personal or family vulnerability to psychotic disorders may need to be especially cautious.

Why the findings matter as cannabis products become stronger

The cannabis landscape has changed substantially in recent decades. Modern products can differ considerably from the cannabis preparations studied in older research, particularly in THC concentration and product diversity.

Edibles, concentrated extracts and other high-potency formulations can make dose estimation difficult for consumers.

This creates a policy challenge. Cannabis regulation that focuses only on whether a product is legal or illegal may overlook an equally important question: how much THC is being delivered, how often and to whom?

Future public-health strategies may need to pay greater attention to potency, product labelling, age restrictions, mental-health warnings and screening for problematic use.

What researchers need to study next

The strongest future studies will need to follow people over long periods and measure cannabis exposure more precisely.

Researchers should ideally track age at first use, frequency, THC potency, duration of use, family psychiatric history and other substance exposure while also assessing emerging mental-health symptoms.

Such research could help answer an especially important question: does reducing or stopping cannabis use after regular exposure change the trajectory of psychosis risk?

More evidence is also needed on medicinal cannabis, different cannabinoid formulations and whether some people are particularly susceptible to THC-related psychiatric effects.

Conclusion: delaying cannabis may not eliminate psychosis risk

The new evidence challenges a reassuring but overly simple idea: that cannabis becomes substantially safer for the brain once a person reaches the mid-20s.

Research increasingly indicates that cannabis use in adulthood can still be associated with earlier onset of psychosis. The relationship appears particularly concerning with frequent and high-potency use, while individual vulnerability plays an important role.

At the same time, the science does not justify claiming that cannabis inevitably causes psychosis. Most users will not develop a psychotic disorder, and observational studies cannot establish causality on their own.

The most responsible interpretation is therefore neither alarmist nor dismissive. Cannabis is not risk-free simply because someone is 25, 30 or older. Nor does cannabis use mean that psychosis is inevitable.

The key lesson is that there is no single birthday at which cannabis-related mental-health risk suddenly disappears. As research continues to clarify how age, potency, frequency, genetics and cumulative exposure interact, people should make decisions based on the broader evidence rather than the assumption that reaching the mid-20s provides a guaranteed safety threshold.